在老年多病理性急性心力衰竭患者中使用-葡萄糖共传输体2型抑制剂:PROFUND-IC注册表
Alicia Guzmán-Carreras1, Andrea María Vellisca-González1, Juan Igor Molina-Puente2
1Servicio de Medicina Interna, Hospital Clínico San Carlos, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Journal of clinical medicine
|June 27, 2024
概括
-葡萄糖共运输体2型抑制剂 (SGLT2is) 在急性心力衰竭和多种并发症住院的老年人中显著降低了12个月的再入院率. 这项研究强调了SGLT2is在这个脆弱患者群体中的好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 急性心力衰竭 (AHF) 是65岁及以上人群住院的主要原因,与显著的发病率和死亡率有关.
- -葡萄糖共运输体2型抑制剂 (SGLT2is) 已在改善心力衰竭 (HF) 患者的生存率和生活质量方面表现出有效性,无论左心室喷射率 (LVEF) 是多少.
- 该研究研究了因AHF而入院的多种病理患者的特征以及SGLT2i治疗对再入院和死亡率的影响.
研究的目的:
- 为了表征成年人多重并发症被录取为AHF.
- 为了描述使用SGLT2治疗的AHF患者群体.is.
- 评估SGLT2i使用与该队列中较低的再入院和死亡率之间的关联.
主要方法:
- 使用PROFUND-IC注册表进行前性研究,分析了750名入院AHF患者的临床和分析数据.
- 描述性和双变体分析比较SGLT2is患者与未接受SGLT2is患者,采用千平方,韦尔奇,费舍尔和威尔科克森测试.
- 卡普兰-梅尔曲线用于12个月再录取和死亡率分析,其次是倾向性得分与混变量对照匹配.
主要成果:
- 在750名患者中,SGLT2被处方给了28%的患者 (平均年龄84岁,58%为女性).
- 接受SGLT2的患者表现出较低的基线入院死亡率 (2.4%对6.9%),12个月死亡率 (6.2%对13%) 和12个月再入院率 (23.8%对38.9%).
- 倾向性得分匹配证实,接受SGLT2is治疗的患者12个月再入院率显著下降 (p = 0.03).
结论:
- 在患有多种病理和急性心力衰竭的老年人中使用SGLT2抑制剂与12个月再入院率显著降低有关.
- 这些发现支持扩大SGLT2is的使用,用于管理复杂的AHF群体,以改善临床结果并减少医疗保健利用率.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Secondary Active Transport
119.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.2K
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180


